logo-loader
viewCytoDyn

CytoDyn to meet with FDA to finalize next steps on leronlimab drug trial for HIV

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors the FDA has requested an in-person meeting to discuss and potentially finalize the biotechnology company’s protocol for a trial of flagship drug leronlimab as a single treatment for HIV patients.

Dr Pourhassan also addresses the company's stagnant share price, and whether this poses a risk.

Quick facts: CytoDyn

Price: 0.302 USD

OTCMKTS:CYDY
Market: OTCMKTS
Market Cap: $117.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Global Energy Metals in London discussing plans to develop cobalt projects...

Global Energy Metals Corporation (CVE:GEMC) (OTCMKTS:GBLEF) CEO Mitchell Smith caught up with Proactive's Andrew Scott while in London to update shareholders on progress within its portfolio of cobalt and battery metal projects. Smith says the firm's well-placed to take advantage of the...

19 hours, 10 minutes ago

2 min read